Go to the list of all blogs
Sergey Savastiouk's Avatar
published in Blogs
Oct 28, 2026
TickeronGET DAILY SIGNALS
Baird Medical (BDMD) Stock Falls -66% Over 30 Days Amid Ongoing Selling Pressure

Baird Medical (BDMD) Stock Falls -66% Over 30 Days Amid Ongoing Selling Pressure

Key Takeaways

  • Baird Medical shares declined roughly 66% over the past 30 days, falling from about $0.77 to around $0.26, driven by sustained selling pressure and thin trading liquidity.
  • The move extends a longer downtrend, with the stock down more than 50% over the past three months and roughly 70% over six months.
  • The slide has continued despite reported revenue growth, underscoring investor concerns about the pace of commercialization and near-term cash generation.
  • Regulatory approvals in markets such as Vietnam, Egypt, and Pakistan have expanded the company's footprint but have not yet translated into meaningful near-term revenue.
  • A Weiss Ratings downgrade to "Sell" in early October and broader micro-cap risk contributed to negative sentiment.
  • For additional detail on the stock's valuation and outlook, explore Baird Medical's Price Targets, Earnings, and Forecast pages.
  • Traders tracking automated strategies may also want to explore Tickeron's Trending AI Robots.

Baird Medical (BDMD) Company Overview and Market Position

Baird Medical Investment Holdings Ltd. is a medical technology company specializing in minimally invasive ablation technologies for solid tumors. Founded in 2012 and headquartered in Guangzhou, China, the company listed on Nasdaq in October 2024 through a business combination. Its lead product, a microwave ablation (MWA) system, is FDA-cleared for soft tissue ablation and is being launched in the United States primarily for the treatment of benign thyroid nodules.

The company's technology has been adopted by a growing list of institutions, including the Mayo Clinic, Columbia University Medical Center, and The George Washington University Hospital. Beyond its core MWA platform, Baird Medical is expanding into irreversible electroporation (IRE) technology through a partnership with Alpmed and is developing an AI-powered robotic ablation system. The company reports a high gross margin of roughly 87%, reflecting a favorable geographic and revenue mix as it diversifies away from its historical concentration in Mainland China. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.

Baird Medical (BDMD) Stock Price Performance: Last 30 Days vs. Quarter

Over the last 30 days, BDMD shares fell from a closing price of approximately $0.77 to around $0.26, a decline of roughly 66%. The move was punctuated by several outsized single-session declines across September and October, a pattern consistent with a thinly traded micro-cap experiencing intense selling pressure rather than a single, isolated catalyst.

The recent drop is part of a broader multi-month downtrend. Over the past three months, the stock has declined more than 50%, and it has lost roughly 70% over six months. This sustained weakness has unfolded despite a sequence of positive operational announcements, indicating that investor concerns about execution, liquidity, and cash generation have outweighed headline progress.

What Drove BDMD Stock Price in the Last 30 Days

Several verified developments shaped the stock's recent decline. In early October, Weiss Ratings downgraded its outlook on Baird Medical to a "Sell" rating, adding to negative sentiment. Around the same time, the company announced regulatory milestones, including Class C device registrations in Vietnam and preliminary approval from Egypt's drug authority, but the shares failed to respond positively as investors questioned how quickly these approvals would convert into revenue.

Broader micro-cap dynamics also weighed on the stock. With a market value in the low tens of millions of dollars and limited daily liquidity, BDMD is highly susceptible to sharp moves. The company's low cash position of roughly $0.29 million as of June 30, 2026 has reinforced concerns about its ability to fund the U.S. commercial ramp without additional capital. Combined, these factors help explain why the stock has continued to slide even as the company reports top-line growth.

What Drove BDMD Stock Performance Over the Last Quarter

The quarterly decline reflects a longer-standing narrative. Baird Medical's 2025 revenue fell 39.2% to $22.5 million as policy-driven pricing pressure and reduced procurement activity in Mainland China weighed on its core business. In response, the company accelerated an international expansion strategy, appointing veteran executive Mark Saxton to lead its U.S. subsidiary and establishing a North American production hub.

First-half 2026 results showed progress, with revenue up 24.6% to roughly $9.9 million and a swing to near breakeven from a large prior-year loss. However, much of that improvement came from aggressive cost-cutting rather than revenue acceleration, and first-half sales remained below 2024 levels. The market has treated the recovery cautiously, and the stock's multi-month slide suggests investors remain unconvinced that regulatory wins and early commercial traction can quickly scale into durable, cash-generating growth.

BDMD Stock Forecast Drivers: What Investors Should Watch Next

Looking ahead, investors are likely to focus on whether Baird Medical can convert its FDA-cleared U.S. presence into recurring sales. The company has said it plans to submit a 510(k) application to the FDA for its first co-developed IRE product by the end of 2026, a milestone that could shape the pipeline narrative. Additional regulatory clearances, physician adoption rates, and updates on the U.S. sales build-out will also be closely watched.

Financial risks remain front and center. The company's modest cash balance raises questions about potential future financing, while the Mainland China policy environment continues to influence the legacy business. Earnings updates, guidance, and any evidence that international revenue can scale sustainably will be key data points. These considerations are informational only and are not intended as investment advice. From what I see, this is important because near-term execution will determine whether the recent regulatory progress can stabilize the valuation.

Using Tickeron AI Tools for Deeper Analysis

In reviewing stocks like this, I frequently consult Tickeron's AI Trading Bots to evaluate automated strategies across similar micro-cap names. The platform provides a range of data-driven options that help put price action into context without replacing fundamental review. It is one of several resources I turn to when assessing momentum and risk factors in thinly traded equities.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: BDMD

Contributor

Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.


BDMD's Indicator enters downward trend

The Aroon Indicator for BDMD entered a downward trend on November 11, 2026. Tickeron's A.I.dvisor identified a pattern where the AroonDown red line was above 70 while the AroonUp green line was below 30 for three straight days. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options. A.I.dvisor looked at 168 similar instances where the Aroon Indicator formed such a pattern. In 148 of the 168 cases the stock moved lower. This puts the odds of a downward move at 88%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

Following a 3-day decline, the stock is projected to fall further. Considering past instances where BDMD declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 83%.

Bullish Trend Analysis

The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where BDMD's RSI Indicator exited the oversold zone, 19 of 25 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 76%.

The Momentum Indicator moved above the 0 level on November 20, 2026. You may want to consider a long position or call options on BDMD as a result. In 32 of 72 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 44%.

The Moving Average Convergence Divergence (MACD) for BDMD just turned positive on November 11, 2026. Looking at past instances where BDMD's MACD turned positive, the stock continued to rise in 20 of 46 cases over the following month. The odds of a continued upward trend are 43%.

Following a +10.62% 3-day Advance, the price is estimated to grow further. Considering data from situations where BDMD advanced for three days, in 70 of 120 cases, the price rose further within the following month. The odds of a continued upward trend are 58%.

BDMD may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of 34 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.081) is normal, around the industry mean (4.142). P/E Ratio (-0.159) is within average values for comparable stocks, (3.291). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (11.253). Dividend Yield (0.000) settles around the average of (0.011) among similar stocks. P/S Ratio (1.371) is also within normal values, averaging (40.124).

The Tickeron PE Growth Rating for this company is 98 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is 98 (best 1 - 100 worst), indicating slightly worse than average price growth. BDMD’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. BDMD’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

Notable companies

The most notable companies in this group are Abbott Laboratories (NYSE:ABT), Medtronic plc (NYSE:MDT), Boston Scientific Corp (NYSE:BSX), Edwards Lifesciences Corp (NYSE:EW).

Industry description

The medical/nursing services includes companies that provide medical-related services such as ambulance services, dialysis centers, respiratory therapy, blood testing and rehabilitation services. DaVita Inc., Chemed Corporation and Guardant Health, Inc. are examples of companies in this industry.

Market Cap

The average market capitalization across the Medical/Nursing Services Industry is 6.17B. The market cap for tickers in the group ranges from 837 to 190.22B. ABT holds the highest valuation in this group at 190.22B. The lowest valued company is DHAI at 837.

High and low price notable news

The average weekly price growth across all stocks in the Medical/Nursing Services Industry was -11%. For the same Industry, the average monthly price growth was -15%, and the average quarterly price growth was -18%. MXCT experienced the highest price growth at 15%, while CODX experienced the biggest fall at -50%.

Volume

The average weekly volume growth across all stocks in the Medical/Nursing Services Industry was -35%. For the same stocks of the Industry, the average monthly volume growth was -2% and the average quarterly volume growth was -21%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 48
P/E Growth Rating: 50
Price Growth Rating: 64
SMR Rating: 89
Profit Risk Rating: 94
Seasonality Score: 16 (-100 ... +100)
AI Patterns 1
View a ticker or compare two or three
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

Industry MedicalNursingServices

Industry
N/A
Address
No.15 Rongtong Street
Phone
+86 13560026976
Employees
146
Web
N/A
Interact to see
Advertisement
Alphabet Inc. (GOOG) , the parent of Google, YouTube, and Google Cloud, is a common stock, not an exchange-traded fund. The central target of $400 is the arithmetic mean of current analyst price targets, which span a wide band from roughly $300 to $500, with the broad average near $397.
AAPL has shown stronger relative performance in recent weeks, holding near record highs while many artificial intelligence (AI)-focused tech stocks sold off. MSFT has lagged the market and now trades below its 50-day moving average amid concerns over heavy AI infrastructure spending.
Bending Spoons reported third-quarter 2026 revenue of $780.22 million, up 125.1% year over year and above the roughly $745.86 million consensus estimate. Earnings per share (EPS) came in at $0.42, beating the $0.26 consensus estimate by $0.16.
GOOG declined roughly 20% over the past 30 days, falling from about $331 to around $264 per share. The sell-off was triggered by Alphabet's third-quarter 2026 report, which revealed slowing Search advertising growth and an earnings miss.
Intel Corporation has delivered dramatically stronger relative price momentum over the past year, while SPY offers broad, diversified market exposure with far lower single-stock volatility. INTC's rally has been driven by a strategic turnaround under new leadership, backed by multi-billion-dollar investments from Nvidia, SoftBank, and the U.S. government.